Temferon

Gene therapy / editing

Stoppedregistry status

Evidence outlook

Development stopped: Phase 1/2 study terminated

The drug's registered studies are all terminated, withdrawn or suspended (NCT03875495: terminated); none completed, so no evidence signal is assigned. Check the registry record for the sponsor's stated reason.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (3)
Glioblastoma
Other / comorbidity

Competitive landscape

This drug's own stage for Glioblastoma: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Temferon: this drugPhase 1/2Gene therapy / editingInterferon-alpha2 (myeloid-specific expression), Interferon-alpha2 (IFN-alpha2) expression in myeloid cellsnot yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)not yet gradedNo reviewed efficacy summary in this indication
NiraparibPhase 3Small moleculePARP1/2not yet gradedNo reviewed efficacy summary in this indication
TNG456Phase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
ZedoresertibPhase 1/2Small moleculeWEE1 kinasenot yet gradedNo reviewed efficacy summary in this indication
AZD1390Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
RalometostatDiscontinuedSmall moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.